Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
From Twitter To Treatment Guidelines, Industry Influence Permeates Medicine

The long arm of the pharmaceutical industry continues to pervade practically every area of medicine, reaching those who write guidelines that shape doctors' practices, patient advocacy organizations, letter writers to the Centers for Disease Control and Prevention and even oncologists on Twitter, according to a series of papers on money and influence published Tuesday in JAMA Internal Medicine.

Published
18 hours ago
From
NPR
Japan: Hepatitis C drug fakes found in Nara drugstore chain

Counterfeits of the hepatitis C drug Harvoni have been found at a drugstore chain in Nara Prefecture, the health ministry said Tuesday. Harvoni is sold by a Japanese unit of U.S. pharmaceutical firm Gilead Sciences Inc. The ingredients of the counterfeits are now under examination.

Published
19 hours ago
From
The Japan Times
The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

The U.S. government could cure most Americans suffering from hepatitis C infections if it simply bought drug maker Gilead Sciences on the stock market rather than purchasing its products in the drug market.

Published
17 January 2017
From
Forbes
The ‘final nail in the coffin’ for Aids?

A surge in the use of preventative drugs is reducing risk but with more than 36m people living with HIV a huge challenge remains.

Published
05 January 2017
From
Financial Times
GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

GlaxoSmithKline PLC’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

Published
20 December 2016
From
Wall Street Journal
Gilead’s Patent Loss to Merck Started With a Broken Friendship

Jury may have been swayed by ‘story of betrayal,’ lawyers say. Gilead will use law, not emotion, to seek to overturn verdict.

Published
19 December 2016
From
Bloomberg
Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

Published
16 December 2016
From
Reuters
The FDA Should Approve Drugs Based on Evidence, Not Emotions

A new bill and Donald Trump could come together to undermine the FDA’s ability to safeguard the public from dangerous new drugs.

Published
15 December 2016
From
Slate
Winners and Losers in the 21st Century Cures Act

Obama signs the biggest health legislation since the Affordable Care Act. What strings are attached?

Published
15 December 2016
From
Poz
Trump is considering a dangerous radical to lead FDA. Here’s why that’s bad news.

Imagine being prescribed a medicine when neither your doctor nor the manufacturer has any clue whether it will actually work — because the government never required it to be tested for effectiveness.

Published
12 December 2016
From
STAT
← First12345...93Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.